Business
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.
FEATURED STORIES
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases
The two companies plan to focus their efforts on targeting several rare diseases.
The COVID-19 pandemic isn’t likely to end soon. Instead, the crisis stage may continue for weeks or even months before business regains some semblance of normality. The good news is that while biotech companies have slowed their hiring initiatives, layoffs remain unlikely at this point. Instead, biotech companies are enhancing flexibility on nearly every front.
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
Troubled Unum Therapeutics announced its fourth quarter and full-year financial report yesterday. Among the news was that it is considering seemingly every possible strategic option, including a sale or merger.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
Sanofi Pasteur and Translate Bio have partnered to develop a novel messenger RNA vaccine for COVID-19, the disease caused by the novel coronavirus.
Specifically, they will be looking at ways to improve processes by speeding up and reducing the cost of manufacturing.
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.